Avi Biopharma Inc - Current report filing (8-K)
March 25 2008 - 4:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported):
March 20, 2008
AVI BioPharma, Inc.
(Exact name of Company as specified in its
charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File No.)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification No.)
|
incorporation)
|
|
|
|
|
One S.W.
Columbia, Suite 1105
Portland,
OR 97258
(Address of principal executive offices)
(503)
227-0554
Registrants telephone number, including area
code
Not
Applicable
(Former name or former address, if changed
since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
o
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 7.01 Regulation
FD Disclosure.
On March 20, 2008, AVI BioPharma, Inc.
(the Company)
completed its acquisition of Ercole Biotech, Inc., a privately
held Delaware corporation. A copy of the
press release issued by the Company announcing the completion of the
acquisition is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial
Statements and Exhibits.
(d)
|
Exhibits
|
|
|
|
|
|
|
|
The
following exhibits are furnished herewith:
|
|
|
|
|
|
|
|
99.1
|
Press
Release dated March 24, 2008.
|
|
|
|
|
|
|
|
2
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Portland, State of Oregon, on March 24, 2008.
|
AVI
BioPharma, Inc.
|
|
|
|
By:
|
/s/
Alan P. Timmins
|
|
|
|
|
|
Alan
P. Timmins
|
|
|
President and Chief Operating Officer
(Principal Operating Officer)
|
3
Exhibit Index
Exhibit
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated March 24, 2008.
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024